Effects of Prior Authorization on Medication Discontinuation Among Medicaid Beneficiaries With Bipolar Disorder

被引:0
|
作者
Zhang, Yuting
Adams, Alyce S. [1 ,2 ]
Ross-Degnan, Dennis [1 ,2 ]
Zhang, Fang [1 ,2 ]
Soumerai, Stephen B. [1 ]
机构
[1] Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Boston, MA 02215 USA
[2] Harvard Pilgrim Hlth Care, Boston, MA USA
基金
美国医疗保健研究与质量局;
关键词
ANGIOTENSIN-RECEPTOR BLOCKERS; STEP-THERAPY; PROGRAM; PHARMACOTHERAPY; SCHIZOPHRENIA; COMORBIDITY; 12-MONTH; DRUGS;
D O I
10.1176/ps.2009.60.4.520
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objective: Few data exist on the cost and quality effects of increased use of prior-authorization policies to control psychoactive drug spending among persons with serious mental illness. This study examined the impact of a prior-authorization policy in Maine on second-generation antipsychotic and anticonvulsant utilization, discontinuations in therapy, and pharmacy costs among Medicaid beneficiaries with bipolar disorder. Methods: Using Medicaid and Medicare utilization data for 2001-2004, the authors identified 5,336 patients with bipolar disorder in Maine (study state) and 1,376 in New Hampshire (comparison state). With an interrupted time-series and comparison group design, longitudinal changes were measured in second-generation antipsychotic and anticonvulsant use; survival analysis was used to examine treatment discontinuations and rates of switching medications. Results: The prior-authorization policy resulted in an 8-percentage point reduction in the prevalence of use of nonpreferred second-generation antipsychotic and anticonvulsant medications (those requiring prior authorization) but did not increase use of preferred agents (no prior authorization) or rates of switching. The prior-authorization policy reduced total pharmacy reimbursements for bipolar disorder by $27 per patient during the eight-month policy period. However, the hazard rate of treatment discontinuation (all bipolar drugs) while the policy was in effect was 2.28 (95% confidence interval= 1.36-4.33) higher than during the prepolicy period, with adjustment for trends in the comparison state. Conclusions: The small reduction in pharmacy spending for bipolar treatment after the policy was implemented may have resulted from higher rates of medication discontinuation rather than switching. The findings indicate that the prior-authorization policy in Maine may have increased patient risk without appreciable cost savings to the state. (Psychiatric Services 60: 520-527, 2009)
引用
收藏
页码:520 / 527
页数:8
相关论文
共 50 条
  • [21] The Impact of Prior Authorization on Buprenorphine Dose, Relapse Rates, and Cost for Massachusetts Medicaid Beneficiaries with Opioid Dependence
    Clark, Robin E.
    Baxter, Jeffrey D.
    Barton, Bruce A.
    Aweh, Gideon
    O'Connell, Elizabeth
    Fisher, William H.
    HEALTH SERVICES RESEARCH, 2014, 49 (06) : 1964 - 1979
  • [22] Substance Abuse and Hospitalization for Mood Disorder Among Medicaid Beneficiaries
    Prince, Jonathan D.
    Akincigil, Ayse
    Hoover, Donald R.
    Walkup, James T.
    Bilder, Scott
    Crystal, Stephen
    AMERICAN JOURNAL OF PUBLIC HEALTH, 2009, 99 (01) : 160 - 167
  • [23] State Variation in the Delivery of Comprehensive Services for Medicaid Beneficiaries with Schizophrenia and Bipolar Disorder
    Jonathan D. Brown
    Allison Barrett
    Kerianne Hourihan
    Emily Caffery
    Henry T. Ireys
    Community Mental Health Journal, 2015, 51 : 523 - 534
  • [24] State Variation in the Delivery of Comprehensive Services for Medicaid Beneficiaries with Schizophrenia and Bipolar Disorder
    Brown, Jonathan D.
    Barrett, Allison
    Hourihan, Kerianne
    Caffery, Emily
    Ireys, Henry T.
    COMMUNITY MENTAL HEALTH JOURNAL, 2015, 51 (05) : 523 - 534
  • [25] Effects of a statewide prior authorization program on Medicaid obstetrical ultrasound claims
    Mcghee, J
    Kay, H
    Norton, J
    Lowery, C
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2003, 189 (06) : S160 - S160
  • [26] Examining the perceived burden of prior authorization of psychotherapeutics among Texas Medicaid prescribers
    Brown, C.
    Rascati, K. L.
    Nwokeji, E. D.
    Corbell, Z. D.
    Phillips, G. A.
    Zachry, W. M.
    VALUE IN HEALTH, 2008, 11 (03) : A134 - A134
  • [27] Coverage and Prior Authorization Policies for Medications for Opioid Use Disorder in Medicaid Managed Care
    Abraham, Amanda J.
    Andrews, Christina M.
    Harris, Samantha J.
    Westlake, Melissa M.
    Grogan, Colleen M.
    JAMA HEALTH FORUM, 2022, 3 (11): : E224001
  • [28] Multimorbidity and COPD Medication Receipt Among Medicaid Beneficiaries With Newly Diagnosed COPD
    Ajmera, Mayank
    Sambamoorthi, Usha
    Metzger, Aaron
    Dwibedi, Nilanjana
    Rust, George
    Tworek, Cindy
    RESPIRATORY CARE, 2015, 60 (11) : 1592 - 1602
  • [29] Medication Adherence Among Adolescents with Bipolar Disorder
    Goldstein, Tina R.
    Krantz, Megan
    Merranko, John
    Garcia, Matthew
    Sobel, Loren
    Rodriguez, Carlos
    Douaihy, Antoine
    Axelson, David
    Birmaher, Boris
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2016, 26 (10) : 864 - 872
  • [30] Effects of prior authorization on statewide Medicaid non-stress testing claims
    Lowery, C
    Kay, H
    Norton, J
    Mcghee, J
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2003, 189 (06) : S160 - S160